TEAM
The Scope Fluidics team are a group of supreme professionals in the fields of biochemistry, microbiology, physics, engineering, law, marketing and business development, finance, human resources management, and project management.
The directions for the Scope Fluidics Group’s development are set by its three-member Management Board, whose composition reflects the organisation’s profile, combining scientific competence with managerial experience.
Management Board
Piotr Garstecki
President of the Management Board
Co-founder of Scope Fluidics. Professor of chemistry and manager. He has led scientific
technical projects in Poland and the United States, specializing in soft matter physics
and microfluidic techniques. Passionate about organizational development and building value by
creating technologies that solve important problems in healthcare.
Marcin Izydorzak
Vice President of the Management Board
Co-founder of Scope Fluidics. Manager. He gained his experience in technology companies,
scientific institutes and pharmaceutical companies. In his professional career,
he has coordinated a number of implementation processes. An enthusiast of risk management and solving difficult problems. At Scope Fluidics, he is responsible for clinical research, intellectual property,
production and registration processes.
Szymon Ruta
Vice-President of the Management Board – Financial Director
A manager with many years of experience in managing capital groups, carrying out M&A transactions, and cooperating with the capital market, including raising capital from international institutions. At Scope Fluidics, he is responsible for the financial division, M&A transactions and investor relations.
placeholder
Supervisory Board
Robert Przytuła
Chairman of the Supervisory Board
A graduate of the Faculty of Mathematics, Mechanics and Computer Science of the University of Warsaw – major: Applications of Mathematics in Finance and Economics. After graduation, from August 1998, employed in the Investment Advisory Department of the Brokerage Office of BGŻ S.A., from the beginning of 2000 as a share analyst. In 2000, he completed post-graduate studies in Financial and Management Accounting. From June 2003 to September 2008 he worked at Skarbiec TFI S.A. – initially as an equity analyst, and later as Director of the Analysis Department. Since March 2009, managing partner of TOTAL FIZ fund.
Andrzej Chądzyński
Member of the Supervisory Board
A manager with many years of experience in the international medical devices market. Responsible among other things for: – product and market development of the medical imaging division; co-creation of strategic plans; preparation and evaluation of M&A projects (Business Development Manager Imaging Division), management of the international medical imaging contrast media division (Business Unit Manager Contrast Media), financial and management controlling of the medical imaging division (approx. EUR 700 million annual turnover), creation and improvement of management information system; co-creation and control of the implementation of financial plans (5-year, annual, quarterly), operational and financial management of companies in Poland, the Czech Republic and Hungary (President of the Management Board of the company in Poland; Finance & Operations Manager Eastern Europe); carrying out, among other things, processes of demerging of business activities (Business Unit Demerger)
Robert Hołyst
Member of the Supervisory Board
Professor Robert Hołyst is the head of the Soft Matter Department of the Institute of Physical Chemistry of the Polish Academy of Sciences. He spent over 6 years working in the USA (University of Washington), France (Ecole Normale Superieure) and in Germany (Max Planck Institute in Mainz). He has supervised and mentored 30 PhD students and over 30 post-doctoral fellows (eight of them are already professors
in Poland, the USA and China). He is the author of over 290 articles in the field of physics, chemistry, biology and biotechnology published in English language journals, three academic textbooks and over 40 granted patents (including some in the USA). He has conducted research for major companies, such as Unilever, Samsung and Mitsui Chemicals. In 2003-2004, he was a shareholder and the CEO of Advanced Science and Technology Investment Group Sp. z o.o. He has experience in managing large projects (about 40 in the years 1993-2021), including four projects from the European Union: NOBLESSE (EUR 3.8 million), ERA CHAIR (EUR 2.5 million), NAMeS (EUR 2.5 million), PD2PI (EUR 2.5 million), NCBiR project (EUR 4.5 million), the TEAM grant from the Foundation for Polish Science (PLN 3 million),
two MAESTRO grants from NCN (PLN 3 million each). He has lectured at Harvard, MIT, Yale,
Princeton, 5 Max Planck Institutes, Ecole Normale in Paris and Lyon, Tokyo University, and Samsung
Advanced. He created cyclical competitions: Dream Chemistry Award and Złoty
Medal of Chemistry. In 2007-2015, he reorganized the Institute of Physical Chemistry of the Polish Academy of Sciences, increasing
effectiveness of research and revenues from projects over 10 times.
Patryk Mikucki
Member of the Supervisory Board
A leader with nearly 20 years of experience in pharmaceutical R&D departments.
Vice President of Clinical Research at Alexion responsible for establishing the model of and national
Clinical Research departments worldwide. Previously engaged with AstraZeneca. operations for 17 years As
Vice President of AstraZeneca Pharma Poland he was involved in the establishment and was responsible for the dynamic
growth of the AstraZeneca Clinical Trials Operations Centre in Warsaw. As Regional Director
(Europe) for Research and Development, he managed national Clinical Trials departments in more than
20 European countries. Since the beginning of his career he has gained experience working in the company’s local and global
units including Sweden, Germany and Ukraine. Patryk Mikucki graduated from the
Faculty of Veterinary Medicine in Lublin with a PhD in veterinary science. He is the
author of several scientific publications in this field. Moreover, he is a graduate of the Warsaw-Illinois
Executive MBA programme.
placeholder
Karolina Radziszewska
Member of the Supervisory Board
Karolina Radziszewska has over 20 years of professional experience,
including in HR management in large international business entities. She specialises in increasing employee
engagement and productivity in companies undergoing
significant organisational change, including mergers and acquisitions, rapid organic growth or
restructuring. Karolina Radziszewska is Vice President of Human Resources for
Skanska’s CEE office. Prior to joining Skanska, she was
People Director at ConsenSys. Earlier, as HR Director and Board Member at
Randstad, she was responsible for HR strategy and processes at EMEA level. She has also gained
experience at such companies as PwC, ZA Puławy and Hewitt Associates. Karolina Radziszewska
holds a master’s degree in economics from the Warsaw School of Economics
Joanna Rzempała
Member of the Supervisory Board
Joanna Rzempała holds a PhD in economics. She is an assistant professor at the
Department of Organisation and Management of the Faculty of Economics, Finance and Management at Szczecin University,
where she lectures on project management. She holds the title of Certified Senior Project Manager
IPMA-B, a certificate of the Minister of Finance for bookkeeping services,
and the PRINCE2 Foundation and GPM project management certificates. She is a member of financial committees
and programme boards in Poland and abroad. She is Vice President of the Management Board of the International Project
Management Association Poland.
Advisory Committee
Prof. Carl Wittwer
A world pioneer in the field of molecular diagnostics – one of the developers of PCR technology, currently associated with the University of Utah, Medical School (USA). One of the most important authorities in the field of molecular diagnostic technology. In the 1990s, he developed the first polymerase chain reaction system, which allowed determining genetic material in less than 15 minutes. Author of numerous publications and scientific studies that inspire developers of diagnostic devices around the world.
Prof. Wilhelm Huck
Expert in microfluidics, construction of synthetic cells, and development of methods for determining reaction rates in individual cells. He carried out postdoctoral research at Harvard University and was director of an institute at Cambridge University. Currently, he heads a research group at Radboud University in the Netherlands. He works with a number of industrial partners to develop droplet microfluidics for single cell analysis. Co-founder of Cambridge-based biotechnology company Sphere Fluidics and a member of the Advisory Board of the Australian Institute of Bioengineering and Nanotechnology.
Sarai Kemp
Originally from Israel, she is a specialist in the development of startups in the field of biotechnology and life sciences, with many years of experience in raising funding for, commercialising and selling projects and running startups in an international environment.
Dr Vincent Linder
Founder of diagnostics startup Claros Diagnostics, a spin-off technology company within Harvard University, sold to an industry investor for over $50 million. Dr Linder is the author of over 300 patents in microfluidic techniques and bedside diagnostics.
placeholder
Dr David Wareham
A world-class clinical microbiologist from London’s Queen Mary University and London’s largest microbiology laboratory. Dr Wareham has extensive experience in the diagnosis, treatment and research of bacterial infections.
Prof. David Weitz
Professor of Physics at Harvard University, one of the most cited physicists in the world. He works on soft matter physics, polymers and microfluidics. He has created many cutting-edge technologies, significantly contributing to the development of single cell sequencing technologies. He has many years of experience working for industry. He has co-founded 20 technology startups, including in the areas of life sciences and medical diagnostics.
Dr Agnieszka Sulikowska
Specialist in medical microbiology, she is a respected consultant in clinical microbiology and hospital-acquired infections, and a board member of the Association for Healthcare Hygiene. She is the author of many scientific publications in the field of bacterial resistance to antibiotics.
placeholder
